DEF: Nuwellis, Inc. Seeks Shareholder Approval for Critical Financial and Listing Actions Amidst Nasdaq Compliance Challenges

Nuwellis, Inc. is convening a special stockholder meeting to vote on proposals crucial for its financial flexibility and continued Nasdaq listing, including warrant exercise approval, an increase in authorized shares, and a potential reverse stock split.

Summary

• A special meeting of stockholders will be held on Monday, August 4, 2025, at 2:00 p.m. U.S. Central Time, conducted virtually via live webcast.
• Stockholders will vote on four key proposals: approval of common stock issuance upon warrant exercise (Proposal 1), approval to increase authorized common stock from 100,000,000 to 200,000,000 shares (Proposal 2), approval of a reverse stock split at a ratio of 1-for-5 to 1-for-70 (Proposal 3), and authorization for meeting adjournments (Proposal 4).
• The Board of Directors unanimously recommends voting FOR all four proposals.
• The company completed a financing transaction (the 'Offering') on June 10, 2025, which generated approximately $5.0 million in gross proceeds for working capital and general corporate purposes.
• Approval of Proposal 1 is necessary for the company to permit the exercise of warrants issued in the Offering, which could provide an additional approximately $3.0 million from Series A Warrants and $0.25 million from Underwriter Warrants.
• Failure to approve Proposal 1 would prevent the company from receiving these additional proceeds and would require it to hold costly stockholder meetings every forty days until approval is obtained.
• The proposed reverse stock split (Proposal 3) is intended to enable the company to comply with Nasdaq Stock Market's continued listing requirements, specifically the minimum bid price rule.
• Nuwellis, Inc. has faced ongoing Nasdaq compliance issues, including non-compliance with the minimum bid price requirement ($1.00) and the minimum stockholders' equity requirement ($2.5 million).
• The company regained compliance with the Stockholders Equity Requirement as of November 12, 2024, and the Minimum Bid Price Requirement as of July 18, 2024 (following a 1-for-35 reverse stock split on June 27, 2024).
• However, on June 18, 2025, the company received a new Nasdaq notice for non-compliance with the minimum bid price requirement, and is not eligible for a compliance period due to prior reverse stock splits. A 1-for-42 reverse stock split was effected on July 3, 2025, and the company is awaiting a hearing before the Nasdaq Panel.
• As of June 9, 2025, the company had 130,154 shares of common stock outstanding and entitled to vote (adjusted to reflect the 1-for-42 reverse stock split effective July 3, 2025).

Sentiment

Score: 3

Explanation: The company is in a distressed state, evidenced by repeated reverse stock splits and ongoing Nasdaq delisting threats. While management is attempting to address these issues through capital raises and corporate actions, the fundamental challenges persist, leading to significant dilution risk and uncertainty regarding long-term viability on a major exchange.

Positives

• The Board of Directors unanimously recommends approval of all four proposals, indicating strong internal alignment on the proposed strategic actions.
• The company successfully completed a financing transaction on June 10, 2025, securing approximately $5.0 million in gross proceeds for operations and general corporate purposes.
• The company previously regained compliance with Nasdaq's Stockholders Equity Requirement as of November 12, 2024, and the Minimum Bid Price Requirement as of July 18, 2024, demonstrating a past ability to address listing deficiencies.
• The virtual meeting format for the Special Meeting is expected to provide ready access and cost savings for stockholders and the company.

Negatives

• The company is facing renewed Nasdaq delisting threats due to its common stock closing bid price falling below $1.00 for 30 consecutive trading days, and is not eligible for a compliance period due to recent reverse stock splits.
• The necessity of a potential reverse stock split (1-for-5 to 1-for-70) indicates persistent struggles with maintaining a sufficient share price to meet Nasdaq listing requirements.
• Approval of the warrant exercise (Proposal 1) could lead to the issuance of up to 1,599,214 additional shares, resulting in significant dilution for existing stockholders.
• Failure to approve the warrant exercise would prevent the company from receiving approximately $3.25 million in additional proceeds, which could adversely impact its ability to fund operations and product development.
• A reverse stock split carries risks, including a potential negative impact on the market for common stock, reduced liquidity, increased costs for selling odd lots, and the possibility that the stock price may not increase proportionally or remain above the minimum bid price.
• The increase in authorized shares (Proposal 2) provides the Board with flexibility to issue additional shares without further stockholder approval, which could lead to future dilutive equity financings.

Risks

• **Nasdaq Delisting Risk**: The company is currently non-compliant with Nasdaq's minimum bid price requirement and is not eligible for a compliance period due to prior reverse stock splits, making delisting a significant and immediate threat. If delisted, the stock would likely trade on the over-the-counter market, leading to reduced liquidity, lower prices, and potential application of 'penny stock' rules.
• **Financial Instability and Funding Dependence**: The company's ability to fund operations and advance clinical trials is contingent on receiving additional proceeds from warrant exercises (approximately $3.25 million), which requires stockholder approval. Failure to secure these funds could severely impact its financial health.
• **Dilution from Share Issuances**: Approval of the warrant exercise could result in the issuance of up to 1,599,214 additional common shares, significantly diluting existing stockholders' ownership interests. The increase in authorized shares also creates the potential for future dilutive equity financings without further stockholder approval.
• **Negative Impact of Reverse Stock Split**: While intended to maintain Nasdaq listing, a reverse stock split may not guarantee a sustained increase in share price, could lead to a greater percentage decline in market price, reduce trading liquidity, and increase transaction costs for stockholders holding odd lots. Some stockholders holding fractional shares may cease to be stockholders.
• **Costs of Non-Compliance**: If the warrant exercise proposal is not approved, the company will incur substantial costs and management time by being required to hold stockholder meetings every forty days until approval is obtained.
• **Mandatory Panel Monitor**: The company is subject to a one-year Mandatory Panel Monitor for the Stockholders Equity Requirement, meaning if it falls out of compliance again within that period, it will not be granted additional time to regain compliance and its securities may be subject to delisting.

Future Outlook

The company's future outlook is focused on maintaining its Nasdaq listing and securing additional capital. It plans to achieve this by obtaining stockholder approval for the exercise of warrants from a recent financing, which would provide additional working capital. Furthermore, the company seeks authorization for a significant increase in its authorized common stock to provide flexibility for future capital raising, equity incentives, and strategic relationships. A potential reverse stock split is also on the table to address ongoing Nasdaq minimum bid price compliance issues, with the Board having discretion on the ratio and timing within twelve months of stockholder approval.

Management Comments

• "Our Board of Directors unanimously recommends that you vote FOR Proposals 1, 2, 3 and 4."
• "We are pleased to utilize the virtual stockholder meeting technology to provide ready access and cost savings for our stockholders and the Company."
• "The Board believes that stockholder approval of the range of reverse stock split ratios (as opposed to approval of a single reverse stock split ratio) provides the Board with maximum flexibility to achieve the purpose of a reverse stock split, as discussed below, and therefore is in the best interests of the Company and its stockholders."
• "The Board believes that maintaining the listing of the Companys common stock on Nasdaq is in the best interests of the Company and its stockholders."
• "Our Board only intends to implement the reverse stock split to the extent it believes necessary to maintain the Companys listing on Nasdaq and to ensure that a sufficient number of shares of our common stock are authorized to satisfy the Companys obligations."

Industry Context

This announcement reflects challenges common to smaller, publicly traded companies, particularly those in the medical device or biotechnology sectors, that are often pre-profitability or have limited revenue streams. Such companies frequently rely on capital markets for funding their operations, research, and development. Maintaining a listing on a major exchange like Nasdaq is crucial for access to capital and investor visibility. The need for repeated reverse stock splits and ongoing compliance issues with listing standards are indicative of a company facing significant financial and market valuation pressures, a scenario not uncommon for firms in early to mid-stages of commercialization or product development within the industry.

Comparison to Industry Standards

• The company's recurring need for reverse stock splits and ongoing struggles with Nasdaq listing compliance (minimum bid price and stockholders' equity) suggest performance significantly below the standards of established, profitable companies in the medical device or healthcare industry.
• Unlike larger, more mature companies such as Medtronic (MDT) or Abbott Laboratories (ABT) which typically maintain stable stock prices and strong financial metrics, Nuwellis's situation indicates a company in a more precarious financial position, akin to early-stage biotech or med-tech startups that are heavily reliant on external financing.
• The low stockholders' equity of $885,000 (as of March 31, 2024) is substantially below the financial health benchmarks of industry leaders and even many smaller, but more stable, publicly traded peers.
• The repeated use of reverse stock splits to maintain listing is a common tactic for companies struggling with low share prices, but it often signals underlying operational or financial weaknesses, contrasting with companies that achieve organic share price appreciation through strong business performance.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the issuance of shares upon warrant exercise and future share issuances if authorized shares are increased. Risk of reduced share price, decreased liquidity, and increased transaction costs due to the proposed reverse stock split and potential Nasdaq delisting. Shareholders holding fractional shares after a reverse split will receive cash and cease to be shareholders.
• **Employees, Officers, and Directors**: May benefit from potential equity incentives if the increase in authorized shares is approved, providing a mechanism for compensation and retention.
• **Company Operations**: The ability to fund ongoing operations, including clinical trials and product development activities, is directly tied to the approval of the warrant exercise, which would unlock additional capital. Failure to secure this funding could severely impede operational progress.

Next Steps

• Hold a Special Meeting of Stockholders on August 4, 2025, to vote on the proposed actions.
• If Proposal 3 (Reverse Split) is approved, the Board has the discretion to effectuate the reverse stock split at a ratio between 1-for-5 and 1-for-70 within twelve months after the stockholder approval date.
• The company is awaiting a hearing before the Nasdaq Panel regarding its current non-compliance with the minimum bid price requirement.
• Publish the final voting results in a current report on Form 8-K within four business days of the Special Meeting.

Key Dates

Recommendation

Keywords

Nuwellis, NUWE, SEC filing, proxy statement, special meeting, warrant exercise, common stock, authorized shares, reverse stock split, Nasdaq listing, delisting risk, dilution, capital raise, corporate governance, financial health, stock market compliance, equity financing